NCT02066961

A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer

A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,533 (actual)
• Sponsor: Astellas Pharma Global Development, Inc. · Industry
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and trigger(s) for treatment changes and to document healthcare resource utilization used to manage treatment-related complications.

Detailed description

Each subject will be followed from the time of enrollment for a minimum of 3 years and a maximum of up to 6 years or until death, whichever comes first.

Conditions

• Prostate Cancer
• Castration-resistant Prostate Cancer
• Metastatic Prostate Cancer

Timeline

• Start date: 2013-12-31
• Primary completion: 2019-11-14
• Completion: 2019-11-14
• First posted: 2014-02-20
• Last updated: 2019-12-20

Locations

93 sites across 27 countries: Algeria, Argentina, Australia, Austria, Brazil, Canada, Colombia, Egypt, France, Germany, Indonesia, Israel, Italy, Lebanon, Mexico, Netherlands, New Zealand, Oman, Peru, Philippines, Saudi Arabia, Singapore, South Korea, Spain, Taiwan, Thailand, United Kingdom